Effectiveness and safety of rivaroxaban in patients with atrial fibrillation and heart failure in clinical practice: an indirect comparison of national and international registries
In clinical practice, AF patients with HF, anticoagulated with rivaroxaban are old, have many comorbidities and have a high thromboembolic risk. Despite this, rates of adverse events are low.
Authors
- Alejandro Recio‐Mayoral (ORCID: https://orcid.org/0000-0002-3646-0661)
- Maria Blasco (ORCID: https://orcid.org/0000-0001-9531-2522)
- Núria Farré (ORCID: https://orcid.org/0000-0003-3110-6572)
- Carles Ràfols
- Juan José Gómez‐Doblas (ORCID: https://orcid.org/0000-0002-9020-639X)
- José María Cepeda (ORCID: https://orcid.org/0000-0002-3303-4501)
- Javier Jiménez‐Candil (ORCID: https://orcid.org/0000-0003-1831-8730)
- Nicolás Manito
- Iñaki Lekuona (ORCID: https://orcid.org/0000-0002-0309-3770)
- José Manuel García Pinilla
- E. Labrador
- M. Castillo Orive
Institutions
- Instituto de Salud Carlos III (ES)
- Bellvitge University Hospital (ES)
- Hospital Universitario Virgen Macarena (ES)
- Hospital Universitario Miguel Servet (ES)
- Hospital de Galdakao (ES)
- Hospital Del Mar (ES)
- Instituto de Investigación Biomédica de Salamanca (ES)
- Hospital Vega Baja (ES)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Instituto de Investigación Biomédica de Málaga (ES)
- Complejo Hospitalario de Ourense (ES)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2025-05-27
- DOI
- https://doi.org/10.3389/fcvm.2025.1451499
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00